Chronic Fatigue Syndrome / ME (Investigational)
Investigational adjunct for myalgic encephalomyelitis/chronic fatigue syndrome; no clinical study identified; conventional pacing and symptom management remain primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for chronic fatigue syndrome (ME/CFS). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for ME/CFS is investigational.
- What evidence exists?
- Tier C (investigational). No clinical study or case report of leech therapy for ME/CFS was identified in PubMed or Europe PMC; claims on practitioner websites are not published evidence. Evidence-based management of ME/CFS per IOM/NAM criteria and CDC guidance: pacing and energy management, treatment of comorbidities (orthostatic intolerance with fluid/salt/compression, sleep disorders, mood symptoms), avoiding graded exercise therapy in those with post-exertional malaise (NICE 2021 reversed prior recommendation), and symptom-targeted pharmacotherapy. Low-dose naltrexone and antiviral trials in selected cases.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Trigger of post-exertional malaise lasting days to weeks from procedure stress
- Worsening of fatigue, brain fog, or orthostatic symptoms
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Risk of vasovagal episode in patients with autonomic dysfunction
- Delay of pacing, energy management, and comorbidity treatment
- Risk of missed underlying treatable cause (thyroid, sleep apnea, anemia, depression)
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Who should not consider this
- Patients without thorough workup for treatable causes (thyroid, anemia, sleep apnea, depression, B12, Lyme, etc.)
- Patients with severe ME/CFS who are bed-bound (procedure-induced PEM risk too high)
- Patients with orthostatic intolerance, POTS, or severe autonomic dysfunction
- Patients on anticoagulants, with hemophilia, or with anemia
- Pregnant patients
- Patients who have not engaged with pacing and energy management
- People with an active infection at the planned application site
- What to ask your clinician
- Have I been worked up for treatable causes (thyroid, sleep apnea, anemia, depression, B12, Lyme)?
- Has my orthostatic intolerance been managed (fluid, salt, compression, sometimes midodrine or fludrocortisone)?
- Have I learned pacing and energy management to avoid post-exertional malaise?
- Am I a candidate for low-dose naltrexone trial?
- Are my comorbidities (sleep, mood, pain) being addressed?
- What evidence specifically supports leech therapy for ME/CFS?
- What is the realistic risk of triggering post-exertional malaise from the procedure?
- Has my diagnosis met established ME/CFS criteria (IOM, CCC, or ICC)?
- When to seek urgent care
- Severe new symptoms after the procedure that do not resolve in days
- Sudden palpitations, severe dizziness, or syncope (worsening orthostatic intolerance)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
- New chest pain, shortness of breath, or signs of cardiac event
- Bleeding from a bite site that soaks through more than one dressing per hour
- New neurologic symptoms not explainable by known ME/CFS pattern
What this does NOT mean
- This is NOT FDA-cleared for chronic fatigue syndrome or ME/CFS.
- No published study was identified that establishes efficacy versus pacing, energy management, or comorbidity treatment; practitioner or patient anecdotes do NOT.
- It does NOT replace workup for treatable causes (thyroid, sleep apnea, anemia, depression).
- It does NOT substitute for evidence-based ME/CFS management per IOM/NAM criteria and CDC guidance.
- It does NOT mean the procedure is risk-free — post-exertional malaise can be triggered by any stressor including a clinical procedure.
Safety cross-references
Clinical Profile
- Category
- Neurological
- ICD-10
- G93.32, R53.82
- Safety tier
- Medium
Evidence Summary
ME/CFS diagnosis follows IOM 2015 criteria (post-exertional malaise, unrefreshing sleep, cognitive impairment or orthostatic intolerance). Management remains supportive: pacing (avoiding post-exertional crashes), addressing comorbid orthostatic intolerance and sleep disorders, and limited symptom-directed pharmacotherapy. No clinical study or case report of leech therapy for ME/CFS was identified in PubMed, Europe PMC, ClinicalTrials.gov or the Baskova and Isakhanyan 2004 monograph; use is investigational, and the neuroimmunologic pathophysiology of ME/CFS is poorly understood and not addressed by leech salivary pharmacology. Graded exercise therapy is no longer recommended due to post-exertional malaise risk; similar caution applies to any intervention requiring repeated sessions.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Severe post-exertional malaise (treatment sessions may worsen)
- Orthostatic intolerance / POTS (risk of syncope)
- Mast cell activation syndrome
- Co-occurring fibromyalgia with allodynia at treatment sites
- Active long COVID with thromboembolic concerns
- Patient unable to commit to post-procedure pacing
Related Conditions
Fibromyalgia
Investigational use only: no controlled clinical study of leech therapy for fibromyalgia was identified, and it is not a primary treatment.
Multiple Sclerosis Fatigue (Investigational Adjunct)
Investigational adjunct for MS-related fatigue; no clinical study was identified; disease-modifying therapy and modafinil/amantadine remain primary.
Complex Regional Pain Syndrome (Type I, Investigational)
Highly investigational adjunct for CRPS Type I; one case report and no controlled study identified; multidisciplinary pain management and physiotherapy remain primary.
Cervical Radiculopathy
Investigational use for cervical radiculopathy; no verifiable published trial specific to this indication.